Inhibition of HDAC and mTOR may improve outcomes for relapsed/refractory Hodgkin lymphoma
The histone deacetylase (HDAC) inhibitor vorinostat (Zolinza) in combination with the mTOR inhibitor sirolimus (Rapamune)…
Browsing: Lymphoma
Many Non-Hodgkin’s Lymphoma patients can skip radiation, collaborative study finds
Skipping radiation and receiving less chemotherapy may become the new standard of care for some…
New therapeutic target identified for rare virus-associated lymphomas
Targeting a “cell survival” protein could be a valuable new approach to treating certain blood…
Study identifies characteristics of infused CAR-T cells associated with efficacy and toxicity in patients with large B-cell lymphoma
Researchers at The University of Texas MD Anderson Cancer Center, USA, have identified molecular and…
Potential cause of immunotherapy-related neurotoxicity
New research has uncovered the previously unknown presence of CD19 — a B cell molecule…
The behaviour of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies…
Excellent research results for CAR-T Cell therapy against Hodgkin lymphoma
CAR-T cell therapy, which attacks cancer cells using a person’s reprogrammed immune cells, has been…
Engineered immune cells recognise, attack human and mouse solid-tumour cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and…
FDA grants accelerated approval to tazemetostat for follicular lymphoma
The Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for…
FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma
The Food and Drug Administration (FDA) granted accelerated approval to selinexor for adult patients with…